Teladoc Health Inc vs 22nd Century Group Inc — how do they compare? Teladoc Health Inc trades at $5.77 (market cap $1.01B), while 22nd Century Group Inc trades at $0.81 (market cap $621.67K). The key difference: Teladoc Health Inc is far larger — about 1624.7× 22nd Century Group Inc's market cap, and Teladoc Health Inc is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Teladoc Health Inc for 39 Days and 22nd Century Group Inc for 32 Days on average.
| TDOC | XXII | |
|---|---|---|
Market Cap | $1.01B | $621.67K |
Volume | 4,668,477 | 45,625 |
Sector | Health | Consumer Staples |
52-Week High | $9.72 | $483.00 |
52-Week Low | $4.47 | $0.80 |
Typical Hold Time | 39 Days | 32 Days |
Enterprise Value | $1.27B | -$3.69M |
Signals from Pluang's Aura AI — not financial advice
Teladoc Health (TDOC) trades at $5.77, up 3.78% today but remains near multi-year lows amid ongoing profitability challenges. The stock shows bearish technical signals with mixed earnings performance, having beaten estimates in two of the last three quarters but posting consistent net losses. Recent management changes include the appointment of a new CFO and legal officer as the company focuses on stabilizing its integrated care business while grappling with BetterHelp segment weakness.
While TDOC trades at discounted valuation multiples (P/S 0.4x, P/B 0.77x) and analysts maintain a $8.83 price target, the path to profitability remains uncertain given seven consecutive quarters of negative earnings. The primary investment thesis hinges on the company's ability to monetize its chronic care platform and achieve sustainable free cash flow generation, though investor sentiment remains cautious amid ongoing losses and competitive pressures in virtual healthcare.
XXII trades at $0.8116, down 8.96% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.08 and P/B of 0.03. Recent news highlights regulatory progress in reduced-nicotine tobacco initiatives in France and Europe.
While analyst consensus is 75% buy with a $1,240 price target suggesting significant upside, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces execution risk in commercializing its reduced-nicotine platform amid ongoing losses.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →